Insider selling
Traded Nov 16 · filed the same day
An Edgewise Therapeutics officer told the SEC about a plan to sell $39K of Edgewise Therapeutics shares around Nov 16, 2026. The shares were not acquired as compensation.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Traded Nov 16, 2026 · Filed Nov 18, 2026
Edgewise Therapeutics's CMO sold $39K of Edgewise Therapeutics shares. The filing references employee stock purchase plan.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell.
open market sale
Code S — open-market or private sale
~$38,840
Shares × reported transaction price
12 days after results of Nov 4, 2026
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
Closed at $43.68 on Nov 16, 2026, 109% above its 52-week low and 10% below its high, after an 8% rise over the previous 30 trading days
52-week range $20.94 (Dec 22, 2025) to $48.74 (Nov 9, 2026), 82% of the way up, from 250 adjusted closes. 30 trading days earlier: $40.30 on Oct 5, 2026. Describes the past only, not a forecast
RSI 55, 18% above its 200-day average, 6% above its 50-day average, 10% below the 52-week high, 20-day volatility 73% a year, against the S&P 500: +21 points over 1 month, +3 points over 3 months, +32 points over 6 months
From the adjusted closes up to Nov 16, 2026. RSI: Wilder's 14-day relative strength index (0 to 100). Averages: the last 50 and 200 closes. Volatility: standard deviation of the last 20 daily returns, annualised. S&P 500: the stock's move minus SPY's between the same dates (21, 63 and 126 trading days). Describes the past only, not a forecast
Footnote references an employee stock purchase plan
Only flagged when a footnote says so; never inferred
Insider selling
Traded Nov 16 · filed the same day
An Edgewise Therapeutics officer told the SEC about a plan to sell $39K of Edgewise Therapeutics shares around Nov 16, 2026. The shares were not acquired as compensation.
Insider filing
Traded Nov 10 · filed the same day
Derivative exercise or conversion — not an open-market buy.
Michael Nofi (Chief Financial Officer) sold ~$202K of Edgewise Therapeutics
Automatic saleEvery dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.